iCAD to Report First Quarter 2021 Financial Results on Wednesday, April 28

April 20, 2021
Category: Press Releases

NASHUA, N.H., April 20, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the first quarter ended March 31, 2021, after the market close, and host a conference call at 4:30pm Eastern Time on Wednesday, April 28.


Wednesday April 28th @ 4:30pm ET

Domestic:

877-407-0784

Inter... Continue reading

Tags: press releases

New Research Confirms iCAD’s ProFound AI Aids Breast Cancer Detection with Digital Breast Tomosynthesis, Improves Radiologists’ Workflow

April 19, 2021
Category: Press Releases

Studies presented at two leading breast imaging conferences demonstrate ProFound AI

helps radiologists identify normal mammograms and those with increased likelihood of malignancy with precision

 

NASHUA, N.H. – April 19, 2021 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that new research supporting the clinical value of ProFound AI® for Digital Breast Tomosynthesis (D... Continue reading

Tags: press releases

iCAD Announces Estimated Q1 Revenues and Upcoming CFO Transition

April 05, 2021
Category: Press Releases

Company expects preliminary estimated revenues to exceed .1 million

Successor CFO search underway


NASHUA, N.H., April 05, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, reported select preliminary, unaudited financial results for the first quarter of 2021. Based on preliminary, unaudited financial information, the Company expects total revenue for the first quarter of 2021 to... Continue reading

Tags: press releases

iCAD Looks Back to Celebrate and Looks Forward to Accelerate

April 01, 2021
Category: iNFORMED - Blog

Recent company milestones further solidify iCAD’s position on the leading-edge of personalized cancer care

 

2020 was a challenging year globally, as countries scrambled to deal with the rapid spread of COVID-19 and a cascade of unforeseen challenges that resulted from its impact. The pandemic changed how people lived, how businesses operated, and how goods and services were delivered across industries. Cancer screening and treatment was brought to a screeching halt in many areas for weeks last year, forcing patients and heal... Continue reading

Tags: iCAD Xoft ProFound IORT Brain COVID
iCAD_2020_Year_in_Review.jpg

New Research Indicates ProFound AI May Reduce Interval Breast Cancer Rates

March 31, 2021
Category: Press Releases

Retrospective analysis published in Journal of Medical Screening suggests that ProFound AI for 2D Mammography could have helped detect 48% of interval cancers and 93% of subgroups that include false-negatives and minimal sign lesions

 

NASHUA, N.H. – March 31, 2021 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that ProFound® AI for 2D Mammography might notably reduce the risk of interval breast canc... Continue reading

Tags: press releases

iCAD Announces FDA Clearance for ProFound AI Version 3.0 for 3D Mammography

March 15, 2021
Category: Press Releases

Company’s third generation AI solution offers significant improvement in algorithm specificity performance and faster processing compared to previous versions of the software

 

Deep learning technology builds upon iCAD’s established leadership in mammography AI

 

NASHUA, N.H. – March 15, 2021 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced... Continue reading

Tags: press releases

New Research Supporting ProFound AI Presented at European Congress of Radiology Online Meeting

March 08, 2021
Category: Press Releases

Company showcased expanded ProFound AI platform, including ProFound AI Risk, the world’s first clinical decision support tool that provides a highly accurate short-term risk estimation specific to each woman

 

NASHUA, N.H. – March 8, 2021 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced new research supporting ProFound AI® was presented at the European Congress of Radiology (ECR) 2021 Online meeting, taking... Continue reading

Tags: press releases

iCAD Announces Closing of .0 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

March 08, 2021
Category: Press Releases

NASHUA, N.H., March 08, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (the “Company”, NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the closing on March 5, 2021 of its previously announced underwritten public offering of 1,393,738 shares of common stock at a public offering price of .00 per share, which included the exercise in full by the underwriters of their option to purchase up to an additional 171,516 shares of common stock. The Company received total gross proceeds from the offering (before deduc... Continue reading

Tags: press releases

iCAD Announces Pricing of .0 Million Public Offering of Common Stock

March 03, 2021
Category: iNFORMED - Blog

NASHUA, N.H., March 03, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (the “Company”, NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the pricing of an underwritten public offering of 1,222,222 shares of its common stock at a public offering price of .00 per share. The gross proceeds of the offering to the Company are expected to be approximately .0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses. In addition, the Company granted the underwrite... Continue reading

Tags: press releases

iCAD to Participate in the Cowen 41st Annual Health Care Conference

March 03, 2021
Category: Press Releases

NASHUA, N.H., March 03, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Michael Klein, iCAD’s Chairman and Chief Executive Officer, will deliver a formal presentation at the Cowen 41st Annual Health Care Conference on Thursday, March 4th at 12:10pm ET and will also conduct one-on-one meetings with investors.


A live audio webcast of the presentation will be available by clicking https://wsw.com/webcast/cowen81/icad/1908885, as well as on the “Eve... Continue reading

Tags: press releases

iCAD Announces Proposed Public Offering of Common Stock

March 02, 2021
Category: Press Releases

NASHUA, N.H., March 02, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (the “Company”, NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by the Company. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, the Company i... Continue reading

Tags: press releases

iCAD Reports Financial Results for Fourth Quarter and Year Ended December 31, 2020

February 24, 2021
Category: Press Releases

Fourth Quarter Revenues of .5 Million Represented 47% Sequential Growth Driven by 70% Growth in ProFound AI ® Product Revenue


ProFound AI® Product Revenue Increased 21% in the Fourth Quarter of 2020 as Compared to 2019 Fourth Quarter Fueled by Launch of ProFound AI ® Risk Assessment Offering


Re... Continue reading

Tags: press releases

iCAD to Report Fourth Quarter 2020 Financial Results on Wednesday, February 24

February 19, 2021
Category: Press Releases

NASHUA, N.H., Feb. 18, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the fourth quarter and year ended December 31, 2020, after the market close, and host a conference call at 4:30pm Eastern Time on Wednesday, February 24.


Wednesday February 24th @ 4:30pmET

Domestic:

 

Continue reading

Tags: press releases

iCAD to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

February 16, 2021
Category: Press Releases

NASHUA, N.H. – February 16, 2021 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Michael Klein, iCAD’s Chairman and Chief Executive Officer, will participate in a fireside chat during the BTIG Virtual MedTech, Digital Health, Life... Continue reading

Tags: press releases

iCAD to Participate in B. Riley Securities Virtual Oncology Investor Conference

January 19, 2021
Category: Press Releases

NASHUA, N.H. – January 19, 2021 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Michael Klein, iCAD’s Chairman and Chief Executive Officer, will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor C... Continue reading

Tags: press releases

iCAD to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event

January 06, 2021
Category: Press Releases

New ProFound AI risk software, offering a 2-year projected risk score to be featured

 

NASHUA, N.H. – January 6, 2021 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will participate in the 10th Annual LifeSci Partners Corporate Access Event, January 6-8 and 11-14, 2021.

 

Michael Klein, Chairman and CEO, will host 1x1 meetings and will participate in a panel, Innovat... Continue reading

Tags: press releases

iCAD Announces Renowned Neuro-Oncologist Santosh Kesari, MD, PhD to Lead Post-Market Study for Treatment of Recurrent Glioblastoma (GBM) with FDA-cleared Xoft Brain IORT Technology to Support Clinical Adoption

December 29, 2020
Category: Press Releases

International Multi-Center Study to Commence January 2021

University of Louisville’s Trial on IORT for Large Brain Lesion Treatments Accelerating

First European Patient Treated for Brain Metastasis with Xoft IORT System

 

NASHUA, N.H. – December 29, 2020 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the appointment of Santosh Kesari, MD, PhD,... Continue reading

Tags: press releases

Solis Mammography Adopts iCAD’s ProFound AI Platform Powered by Panorama with Short-Term Breast Cancer Risk Assessment Solution

December 10, 2020
Category: Press Releases

Agreement Positions Both Companies for Growth; Leading-edge AI Technology to be Installed Across Largest Independent Provider of Mammography and Breast Health Services’ Network

 

NASHUA, NH and DALLAS, TX – December 10, 2020 –  iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, and SolisMammography, the largest independent provider of mammography and breast health services in the United States, today announce... Continue reading

Tags: press releases

iCAD Hosting Investor Webinar on Expanded ProFound AI Portfolio with New Breast Cancer Risk Assessment Solution

December 03, 2020
Category: Press Releases

Leading Clinical Experts Discuss Advancing Personalized Breast Cancer Screening and Detection with Newly Launched ProFound AI Risk

 

Added Market Growth Opportunity Presented by Pioneering AI Breast Cancer Risk Offering

 

Webinar Taking Place on Monday, December 7 @ 11am ET

 

NASHUA, N.H. – December 3, 2020 –  iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovativ... Continue reading

Tags: press releases

iCAD Highlights Expanded Suite of Leading Breast Health AI Solutions at Virtual RSNA 2020

November 30, 2020
Category: Press Releases

Groundbreaking ProFound AI Risk Helps Transform Breast Cancer Screening from an Age-Based Paradigm to Risk-Adapted Precision Screening, Individualized for Each Woman

 

NASHUA, N.H. – November 30, 2020 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that the Company is showcasing its leading Breast Health Solutions, including the expanded ProFound AI® platform powered by Panorama, at the 106th Scientif... Continue reading

Tags: press releases

© 2020, iCAD Inc.  All rights reserved.  iCAD, the iCAD logo, PowerLook, ProFound AI, ProFound, Xoft, the Xoft logo, Axxent, Electronic Brachytherapy System and eBx are trademarks of iCAD, Inc. Reproduction of any of the material contained herein in any format or media without the express written permission of iCAD, Inc. is prohibited.